View highlights and coverage from leading international Neurology congresses
It was an honour to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) around his presentation, a sub analysis of the OPTIMUM study (ClinicalTrials.gov identifier: NCT02425644), entitled: P0071 – Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study. Questions […]
We were delighted to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) about his highlights from the MSVirtual2020 meeting. Disclosures: Dr Kappos reports receiving grants from Actelion, Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, CSL Behring, Desitin, Eisai, Excemed, Genzyme, INNO Swiss, Japan Tabacco, Merck, Novartis, Roche, Pfizer, Receptos, Sanofi, Santhera and […]
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. What is known about the role of inflammation in the […]
Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease. Questions 1. Could you tell us about the design of your phase […]
It was a pleasure to speak with Camille Carroll (University of Plymouth, Plymouth, UK) about her late-breaking presentation entitled: Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): results of a double-blind, randomised, placebo-controlled futility study. ClinicalTrials.gov Identifier: NCT02787590. Questions What was the scientific rationale for investigating simvastatin as a neuroprotective treatment for Parkinson’s disease (PD)? (0:06) […]
Alisdair Coles (University of Cambridge, Cambridge, UK) shares exciting phase II findings that highlight the potential of retinoid-X receptor agonists to promote remyelination in relapsing-remitting multiple sclerosis. The interview focuses on his late-breaking presentation entitled: LB01.02 – Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis. Study […]
It was a pleasure to hear from David Leppert (University Hospital Basel and University of Basel, Basel, Switzerland) on his late-breaking presentation about the exciting potential of neutrophil granulocyte markers in the cerebrospinal fluid to differentiate neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody disease (MOGAD) from multiple sclerosis (MS) in the acute disease phase. […]
We were fortunate to have the opportunity to speak with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) following her session entitled: Update on Recent Clinical Trials – Parkinson’s Disease. Questions 1. Could you give us a brief overview of the role of α-synuclein in the pathogenesis of Parkinson’s disease (PD) and its potential […]
Get the latest clinical insights from touchNEUROLOGY
